Alembic Pharmaceuticals reports Q4 earnings, shares dip after profit decline

Alembic Pharmaceuticals Ltd has announced its financial results for the fourth quarter, reporting a consolidated revenue of 17.70 billion rupees and a net profit of 1.57 billion rupees. Despite steady revenue growth, the company's shares fell by 2 percent following the profit decline.  

Key highlights  

- Quarterly revenue performance  
  Alembic Pharmaceuticals posted revenue of 17.70 billion rupees from operations in the fourth quarter, reflecting stable growth in its pharmaceutical business.  

- Profitability and earnings trend  
  The company reported a consolidated profit of 1.57 billion rupees, marking a decline compared to previous quarters, which contributed to the stock price drop.  

- Dividend declaration  
  A final dividend of 11 rupees per share has been announced, reinforcing Alembic Pharmaceuticals' commitment to rewarding investors.  

- Market reaction and investor sentiment  
  Following the earnings announcement, Alembic Pharmaceuticals shares fell by 2 percent, reflecting investor concerns over the profit decline and future growth prospects.  

Sources: CNBC-TV18, MarketScreener, Alembic Pharmaceuticals Ltd official reports